125 related articles for article (PubMed ID: 38344808)
1. KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker.
Kreis NN; Moon HH; Wordeman L; Louwen F; Solbach C; Yuan J; Ritter A
Crit Rev Clin Lab Sci; 2024 Feb; ():1-31. PubMed ID: 38344808
[TBL] [Abstract][Full Text] [Related]
2. Mitotic Centromere-Associated Kinesin (MCAK/KIF2C) Regulates Cell Migration and Invasion by Modulating Microtubule Dynamics and Focal Adhesion Turnover.
Moon HH; Kreis NN; Friemel A; Roth S; Schulte D; Solbach C; Louwen F; Yuan J; Ritter A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830827
[TBL] [Abstract][Full Text] [Related]
3. KIF2C: An important factor involved in signaling pathways, immune infiltration, and DNA damage repair in tumorigenesis.
Li RQ; Yang Y; Qiao L; Yang L; Shen DD; Zhao XJ
Biomed Pharmacother; 2024 Feb; 171():116173. PubMed ID: 38237349
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of MCAK/Kif2C cancer mutations using high-throughput microscopic analysis.
Wagenbach M; Vicente JJ; Ovechkina Y; Domnitz S; Wordeman L
Mol Biol Cell; 2020 Mar; 31(7):580-588. PubMed ID: 31746663
[TBL] [Abstract][Full Text] [Related]
5. Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis.
Shimo A; Tanikawa C; Nishidate T; Lin ML; Matsuda K; Park JH; Ueki T; Ohta T; Hirata K; Fukuda M; Nakamura Y; Katagiri T
Cancer Sci; 2008 Jan; 99(1):62-70. PubMed ID: 17944972
[TBL] [Abstract][Full Text] [Related]
6. Multi-omics analysis of kinesin family member 2C in human tumors: novel prognostic biomarker and tumor microenvironment regulator.
Zhang B; Liu P; Li Y; Hu Q; Li H; Pang X; Wu H
Am J Cancer Res; 2022; 12(11):4954-4976. PubMed ID: 36504885
[TBL] [Abstract][Full Text] [Related]
7. Mitotic centromere-associated kinase (MCAK/Kif2C) regulates cellular senescence in human primary cells through a p53-dependent pathway.
Gwon MR; Cho JH; Kim JR
FEBS Lett; 2012 Nov; 586(23):4148-56. PubMed ID: 23098759
[TBL] [Abstract][Full Text] [Related]
8. KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
Liu S; Ye Z; Xue VW; Sun Q; Li H; Lu D
BMC Cancer; 2023 Apr; 23(1):307. PubMed ID: 37016301
[TBL] [Abstract][Full Text] [Related]
9. KIF2C promotes the proliferation of hepatocellular carcinoma cells
Gao Z; Jia H; Yu F; Guo H; Li B
Exp Ther Med; 2021 Oct; 22(4):1094. PubMed ID: 34504548
[TBL] [Abstract][Full Text] [Related]
10. KIF2C promotes clear cell renal cell carcinoma progression via activating JAK2/STAT3 signaling pathway.
Deng H; Gong X; Ji G; Li C; Cheng S
Mol Cell Probes; 2023 Dec; 72():101938. PubMed ID: 37863123
[TBL] [Abstract][Full Text] [Related]
11. Kinesin family member 2C aggravates the progression of hepatocellular carcinoma and interacts with competing endogenous RNA.
Zhang GP; Shen SL; Yu Y; Yue X; Hu WJ; Li SQ
J Cell Biochem; 2020 Nov; 121(11):4419-4430. PubMed ID: 32056305
[TBL] [Abstract][Full Text] [Related]
12. KIF2C is a Biomarker Correlated With Prognosis and Immunosuppressive Microenvironment in Human Tumors.
Zhang X; Li Y; Hu P; Xu L; Qiu H
Front Genet; 2022; 13():891408. PubMed ID: 35685442
[TBL] [Abstract][Full Text] [Related]
13. Kinesin Kif2C in regulation of DNA double strand break dynamics and repair.
Zhu S; Paydar M; Wang F; Li Y; Wang L; Barrette B; Bessho T; Kwok BH; Peng A
Elife; 2020 Jan; 9():. PubMed ID: 31951198
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Kinesin Family Member 2C as a Proto-Oncogene in Cervical Cancer.
Yang J; Wu Z; Yang L; Jeong JH; Zhu Y; Lu J; Wang B; Wang N; Wang Y; Shen K; Li R
Front Pharmacol; 2021; 12():785981. PubMed ID: 35153749
[TBL] [Abstract][Full Text] [Related]
15. Identification of aberrantly methylated differentially expressed genes and pro-tumorigenic role of KIF2C in melanoma.
Huang CH; Han W; Wu YZ; Shen GL
Front Genet; 2022; 13():817656. PubMed ID: 35991567
[No Abstract] [Full Text] [Related]
16. Down regulated oncogene
Mo S; Fang D; Zhao S; Thai Hoa PT; Zhou C; Liang T; He Y; Yu T; Chen Y; Qin W; Han Q; Su H; Zhu G; Luo X; Peng T; Han C
Ann Transl Med; 2022 Feb; 10(3):151. PubMed ID: 35284538
[TBL] [Abstract][Full Text] [Related]
17. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma.
Bai Y; Xiong L; Zhu M; Yang Z; Zhao J; Tang H
Cancer Biomark; 2019; 24(3):371-382. PubMed ID: 30883337
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of the effects of KIF2C on prognosis, biological functions and immune infiltration in PAAD.
Xiong J; Wu R; He A; Hou P; Wang J; Zhang R; Liao W; Wu L; Li E
Tissue Cell; 2022 Oct; 78():101900. PubMed ID: 36029726
[TBL] [Abstract][Full Text] [Related]
19. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas.
Bie L; Zhao G; Wang YP; Zhang B
Clin Neurol Neurosurg; 2012 May; 114(4):356-60. PubMed ID: 22130050
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle dysregulation with overexpression of KIF2C/MCAK is a critical event in nasopharyngeal carcinoma.
Zuo X; Meng P; Bao Y; Tao C; Wang Y; Liu X; Bu Y; Zhu J
Genes Dis; 2023 Jan; 10(1):212-227. PubMed ID: 37013060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
